

**Appendix Table F78. Comparative effectiveness of tolterodine-ER 4mg/day vs. fesoterodine, evidence secondary data analysis**

Outcome	Reference	Dose of Fesoterodine, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)	Evidence
Discontinued prematurely	Chapple, 2008 <sup>260</sup>	8	9/290	14/287	0.64 (0.28; 1.45)	-0.018 (-0.050; 0.014)			Insufficient
Treatment response	Sand, 2009 <sup>372</sup>	8	140/227	291/452	0.96 (0.85; 1.08)	-0.027 (-0.104; 0.050)			Low
		4	140/227	251/434	1.07 (0.94; 1.21)	0.038 (-0.040; 0.117)			Low
Back pain	Sand, 2009 <sup>372</sup>	8	1/227	4/452	0.50 (0.06; 4.43)	-0.004 (-0.017; 0.008)			Low
		4	1/227	9/434	0.21 (0.03; 1.67)	-0.016 (-0.032; 0.000)			Low
Constipation	Chapple, 2008 <sup>260</sup>	8	8/290	13/287	0.61 (0.26; 1.45)	-0.018 (-0.048; 0.013)			Insufficient
	Sand, 2009 <sup>372</sup>	8	6/227	24/452	0.50 (0.21; 1.20)	-0.027 (-0.056; 0.003)			Low
		4	6/227	20/434	0.57 (0.23; 1.41)	-0.020 (-0.048; 0.009)			Low
Cough	Sand, 2009 <sup>372</sup>	8	5/227	5/452	1.99 (0.58; 6.81)	0.011 (-0.010; 0.032)			Low
		4	5/227	7/434	1.37 (0.44; 4.25)	0.006 (-0.017; 0.028)			Low
Diarrhea	Sand, 2009 <sup>372</sup>	8	3/227	6/452	1.00 (0.25; 3.94)	0.000 (-0.018; 0.018)			Low
		4	3/227	7/434	0.82 (0.21; 3.14)	-0.003 (-0.022; 0.016)			Low
Dizziness	Sand, 2009 <sup>372</sup>	8	4/227	5/452	1.59 (0.43; 5.87)	0.007 (-0.013; 0.026)			Low
		4	4/227	4/434	1.91 (0.48; 7.57)	0.008 (-0.011; 0.028)			Low
Dry eye	Chapple, 2008 <sup>260</sup>	8	1/290	12/287	0.08 (0.01; 0.63)	-0.038 (-0.062; -0.014)	-26 (-70; -16)	-38 (-62; -14)	Insufficient
	Sand, 2009 <sup>372</sup>	8	1/227	10/452	0.20 (0.03; 1.55)	-0.018 (-0.034; -0.002)	-56 (-605; -30)	-18 (-34; -2)	Low
		4	1/227	6/434	0.32 (0.04; 2.63)	-0.009 (-0.023; 0.005)			Low

**Appendix Table F78. Comparative effectiveness of tolterodine-ER 4mg/day vs. fesoterodine, evidence secondary data analysis (continued)**

Outcome	Reference	Dose of Fesoterodine, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)	Evidence
Dry mouth	Chapple, 2008 <sup>260</sup> Sand, 2009 <sup>372</sup>	8	49/290	97/287	0.50 (0.37; 0.68)	-0.169 (-0.239; -0.099)	-6 ( -10; -4)	-169 (-239; -99)	Insufficient
		8	37/227	155/452	0.48 (0.34; 0.66)	-0.180 (-0.245; -0.115)	-6 ( -9; -4)	-180 (-245; -115)	Low
		4	37/227	89/434	0.79 (0.56; 1.13)	-0.042 (-0.103; 0.019)			Low
Dry throat	Chapple, 2008 <sup>260</sup> Sand, 2009 <sup>372</sup>	8	3/290	8/287	0.37 (0.10; 1.38)	-0.018 (-0.040; 0.005)			Insufficient
		8	2/227	10/452	0.40 (0.09; 1.80)	-0.013 (-0.032; 0.005)			Low
		4	2/227	4/434	0.96 (0.18; 5.18)	0.000 (-0.016; 0.015)			Low
Fatigue	Chapple, 2008 <sup>260</sup> Sand, 2009 <sup>372</sup>	8	10/290	1/287	9.90 (1.28; 76.81)	0.031 (0.009; 0.053)	32 (19;112)	31 (9; 53)	Insufficient
		8	7/227	1/452	13.94 (1.73; 112.60)	0.029 (0.006; 0.052)	35 (19; 175)	29 (6; 52)	Low
		4	7/227	5/434	2.68 (0.86; 8.34)	0.019 (-0.005; 0.044)			Low
Headache	Sand, 2009 <sup>372</sup>	8	13/227	13/452	1.99 (0.94; 4.22)	0.029 (-0.005; 0.062)			Low
		4	13/227	21/434	1.18 (0.60; 2.32)	0.009 (-0.027; 0.045)			Low
Increased alanine aminotransferase	Chapple, 2008 <sup>260</sup>	8	0/290	6/287	0.08 (0.00; 1.35)	-0.021 (-0.039; -0.003)	-48 (-232; -26)	-21 (-39; -3)	Insufficient
Nasopharyngitis	Chapple, 2008 <sup>260</sup> Sand, 2009 <sup>372</sup>	8	10/290	5/287	1.98 (0.69; 5.72)	0.017 (-0.009; 0.043)			Insufficient
		8	8/227	6/452	2.65 (0.93; 7.56)	0.022 (-0.004; 0.048)			Low
		4	8/227	14/434	1.09 (0.47; 2.57)	0.003 (-0.026; 0.032)			Low
Nausea	Sand, 2009 <sup>372</sup>	8	3/227	11/452	0.54 (0.15; 1.93)	-0.011 (-0.032; 0.009)			Low
		4	3/227	4/434	1.43 (0.32; 6.35)	0.004 (-0.013; 0.021)			Low
	Chapple, 2008 <sup>260</sup>	8	6/290	4/287	1.48 (0.42; 5.21)	0.007 (-0.015; 0.028)			Insufficient

**Appendix Table F78. Comparative effectiveness of tolterodine-ER 4mg/day vs. fesoterodine, evidence secondary data analysis (continued)**

Outcome	Reference	Dose of Fesoterodine, mg/day	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)	Evidence
URI	Sand, 2009 <sup>372</sup>	8	2/227	8/452	0.50 (0.11; 2.32)	-0.009 (-0.026; 0.008)			Low
		4	2/227	12/434	0.32 (0.07; 1.41)	-0.019 (-0.038; 0.001)			Low
UTI	Sand, 2009 <sup>372</sup>	8	4/227	24/452	0.33 (0.12; 0.94)	-0.035 (-0.062; -0.009)	-28 (-116; -16)	-35 (-62; -9)	Low
		4	4/227	18/434	0.42 (0.15; 1.24)	-0.024 (-0.049; 0.002)			Low